PremiumThe FlyBioNTech price target raised to $145 from $134 at H.C. Wainwright Strategic Partnership with BMY Boosts BioNTech’s Oncology Prospects and Financial Stability BNT327 deal bolsters BioNTech’s competitive position, says Leerink PremiumCompany AnnouncementsBioNTech and Bristol Myers Squibb Partner for Global Development of BNT327 Promising Efficacy and Safety of BioNTech’s BNT324 Supports Buy Rating BioNTech, Bristol Myers partner to co-develop BNT327 PremiumThe FlyBioNTech initiated with a Neutral at Goldman Sachs BioNTech to Showcase Oncology Pipeline Progress at ASCO 2025 CDC removes healthy children, pregnant women from COVID vaccine schedule 
